Janus Henderson Group PLC Allakos Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $57 - $149	27 Added 0.08%	33,566 $76,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $367 - $535	-102 Reduced 0.3%	33,539 $146,000
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $67,256 - $129,351	15,641 Added 86.89%	33,641 $149,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $101,880 - $151,560	18,000 New	18,000 $151,000
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $8.41 Million - $110 Million	-983,329 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$76.53 - $110.43 $12.4 Million - $17.8 Million	161,606 Added 19.67%	983,329 $104 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $23.4 Million - $31.3 Million	274,289 Added 50.1%	821,723 $70.1 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $60.1 Million - $84.1 Million	547,434 New	547,434 $62.8 Million
Q4 2019 Feb 18, 2020	SELL	$66.49 - $137.73 $21.1 Million - $43.7 Million	-317,466 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $9.84 Million - $28.5 Million	317,466 New	317,466 $25 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.